Gallagher Neil 4

What Happened

• Neil Gallagher, a director of Foghorn Therapeutics, was granted a derivative equity award covering 28,000 shares on 2026-06-24. The Form 4 reports the award at $4.08 per share for a reported total of $114,240. The filing classifies the transaction as an award/grant (code A) of a derivative security.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-25 (appears timely).
• Award: 28,000 derivative shares at $4.08 per share; reported value $114,240.
• Vesting: The option vests in full on the first anniversary of the grant date, subject to continued service on the board (footnote F1).
• Shares owned after the transaction: not specified in this Form 4.
• Transaction type codes: A (award/grant); instrument reported as a derivative.

Context

• The filing indicates an option-style derivative award that vests after one year rather than an immediate open-market purchase or sale. Such grants are typically compensation for board service; they do not reflect an immediate change in market exposure unless exercised or sold later.